K. Palmer

发表

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

D. Neuberg, D. Kufe, D. DeAngelo, 2016, Science Translational Medicine.

LYMPHOID NEOPLASIA Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma

L. Yin, R. Clark, D. Kufe, 2015 .

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.

L. Yin, R. Clark, D. Kufe, 2014, Blood.

Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets.

T. Konry, N. Cohen, P. Sabhachandani, 2016, Biomicrofluidics.

MUC1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism

D. Kufe, E. Anastasiadou, M. Bar‐Natan, 2018, Journal of cellular and molecular medicine.

MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs

F. Slack, D. Tenen, D. Kufe, 2017, Leukemia.

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.

P. Pandolfi, D. Kufe, R. Joyce, 2017, Blood.

DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions

D. Neuberg, D. Kufe, D. DeAngelo, 2015 .

MUC 1 Inhibition Leads to Decrease in PD-L 1 Levels via Up-Regulation of miRNAs

F. Slack, D. Kufe, E. Anastasiadou, 2016 .

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1

D. Kufe, I. Ghobrial, M. Bar‐Natan, 2014, British journal of haematology.

MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs

F. Slack, D. Kufe, E. Anastasiadou, 2016 .